Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 7/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | UGCG | Q16739 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564226 | 0.80 | AAK1 (0.39) | GRM2ACACBACACAAAK1 | |
| SCHEMBL7112784 | 0.80 | SCN5A (0.35) | SYK | |
| SCHEMBL5563061 | 0.80 | BRAF (0.40) | — | |
| SCHEMBL7047983 | 0.79 | AAK1 (0.33) | SYKAAK1 | |
| SCHEMBL7044468 | 0.78 | GRM2 (0.35) | GRM2AAK1 | |
| SCHEMBL5562067 | 0.78 | AAK1 (0.36) | GRM2AAK1UGCG | |
| SCHEMBL5557609 | 0.78 | AAK1 (0.38) | GRM2ACACBACACAAAK1 | |
| SCHEMBL7109630 | 0.76 | CSF1R (0.38) | AAK1 | |
| SCHEMBL5563264 | 0.75 | AAK1 (0.41) | ACACBACACAAAK1UGCG | |
| SCHEMBL7113350 | 0.75 | RXRA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |